ERBB2 and breast cancer: Table 1 summarized the clinicopathological features of BCLM patients according to breast cancer subtype. HR+/HER2−, HR−/HER2+, HR+/HER2+ and triple-negative subtypes comprised 46.0% (253), 19.1% (105), 22.4% (123) and 12.5% (69) of BCLM patients, respectively. Compared with other groups, HR+/HER2− patients with BCLM were less likely to present with de novo MBC (P = 0.000). Besides, HR+ (HR+/HER2− and HR+/HER2+) patients with BCLM had a higher rate of bone metastases than HR− (HR−/HER2+ and triple-negative) patients (P = 0.020).